Trading Stocks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TRXX 52 high is .40
Hey Carlito!!
TRXX NITE at .08
he is getting pounded
TRXX flippers gone IMO!
Recent news for PCHM Feb 18, 2009
www.companiesandmarkets.com: PharmChem Inc-Financial Company Report
Feb 18, 2009 (M2 PRESSWIRE via COMTEX) -- -www.companiesandmarkets.com adds new report: PharmChem Inc-Financial Company Report
Financial Company Reports contain the company's contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues. The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, day's sales outstanding, day's outstanding inventory, cash and short-term investments per share and total common shares outstanding. Finally the report includes quarterly book value per share vs. share price. Much of the information contained in the report is included in both tabular and graphic formats.
Financial Reports deliver key sophisticated analytical ratios and performance analyses for public biomedical companies. Each report provides an in depth virtual snapshot of a company, enabling the user to better understand its financial position.
Scope of the report:
Each Life Science Analytics' Financial Report provides extensive information on a company's financial health including:
Company contact information and business overview Stock performance history Dividend history Price and volume figures, including key price ratios relative to earnings, book value ratios and comparisons, sales, cash flow, and share price Historical market-related data including relative strength, valuation, common and diluted shares are presented in graphical form.
Each report provides extensive data on return ratios, financial strength, and growth ratios. Convenient historical tables on quarterly and annual income statements, balance sheets and cash flow statements are also included.
Key benefits:
Data in each Financial Report is presented in both tabular and graphical format providing the user with an efficient assessment of a company's historical performance.
Stay ahead of the competition by accessing the latest financial intelligence.
Sophisticated financial analysis ratios provide a quick insight into management's effectiveness and the company's ability to meet its short-term obligations.
http://www.companiesandmarkets.com/link.asp?id=L5JOW4WR561497
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 7813 784 393 Fax: +44 1536 790 144 e-mail: info@companiesandmarkets.com WWW: http://www.companiesandmarkets.com/link.asp?id=L5JOW4WR561497
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Recent news for PCHM Feb 18, 2009
www.companiesandmarkets.com: PharmChem Inc-Financial Company Report
Feb 18, 2009 (M2 PRESSWIRE via COMTEX) -- -www.companiesandmarkets.com adds new report: PharmChem Inc-Financial Company Report
Financial Company Reports contain the company's contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues. The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, day's sales outstanding, day's outstanding inventory, cash and short-term investments per share and total common shares outstanding. Finally the report includes quarterly book value per share vs. share price. Much of the information contained in the report is included in both tabular and graphic formats.
Financial Reports deliver key sophisticated analytical ratios and performance analyses for public biomedical companies. Each report provides an in depth virtual snapshot of a company, enabling the user to better understand its financial position.
Scope of the report:
Each Life Science Analytics' Financial Report provides extensive information on a company's financial health including:
Company contact information and business overview Stock performance history Dividend history Price and volume figures, including key price ratios relative to earnings, book value ratios and comparisons, sales, cash flow, and share price Historical market-related data including relative strength, valuation, common and diluted shares are presented in graphical form.
Each report provides extensive data on return ratios, financial strength, and growth ratios. Convenient historical tables on quarterly and annual income statements, balance sheets and cash flow statements are also included.
Key benefits:
Data in each Financial Report is presented in both tabular and graphical format providing the user with an efficient assessment of a company's historical performance.
Stay ahead of the competition by accessing the latest financial intelligence.
Sophisticated financial analysis ratios provide a quick insight into management's effectiveness and the company's ability to meet its short-term obligations.
http://www.companiesandmarkets.com/link.asp?id=L5JOW4WR561497
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 7813 784 393 Fax: +44 1536 790 144 e-mail: info@companiesandmarkets.com WWW: http://www.companiesandmarkets.com/link.asp?id=L5JOW4WR561497
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
TRXX .05 coming
TY C & D, I'm ready, sometimes a little early to the party but hey gotta play to win!!
www.companiesandmarkets.com: PharmChem Inc-Financial Company Report
Feb 18, 2009 (M2 PRESSWIRE via COMTEX) -- -www.companiesandmarkets.com adds new report: PharmChem Inc-Financial Company Report
Financial Company Reports contain the company's contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues. The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, day's sales outstanding, day's outstanding inventory, cash and short-term investments per share and total common shares outstanding. Finally the report includes quarterly book value per share vs. share price. Much of the information contained in the report is included in both tabular and graphic formats.
Financial Reports deliver key sophisticated analytical ratios and performance analyses for public biomedical companies. Each report provides an in depth virtual snapshot of a company, enabling the user to better understand its financial position.
Scope of the report:
Each Life Science Analytics' Financial Report provides extensive information on a company's financial health including:
Company contact information and business overview Stock performance history Dividend history Price and volume figures, including key price ratios relative to earnings, book value ratios and comparisons, sales, cash flow, and share price Historical market-related data including relative strength, valuation, common and diluted shares are presented in graphical form.
Each report provides extensive data on return ratios, financial strength, and growth ratios. Convenient historical tables on quarterly and annual income statements, balance sheets and cash flow statements are also included.
Key benefits:
Data in each Financial Report is presented in both tabular and graphical format providing the user with an efficient assessment of a company's historical performance.
Stay ahead of the competition by accessing the latest financial intelligence.
Sophisticated financial analysis ratios provide a quick insight into management's effectiveness and the company's ability to meet its short-term obligations.
http://www.companiesandmarkets.com/link.asp?id=L5JOW4WR561497
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 7813 784 393 Fax: +44 1536 790 144 e-mail: info@companiesandmarkets.com WWW: http://www.companiesandmarkets.com/link.asp?id=L5JOW4WR561497
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2009 M2 COMMUNICATIONS LTD
-0-
Zero resistance, gonna be one to talk about for some time IMO!!
TRXX l2 snapshot
TRXX l2 snapshot
l2 snapshot
TRXX .012 ,,RM into a stem cell co... !!!!
Posted by: rudaddy2003 Date: Monday, April 20, 2009 2:22:56 PM
In reply to: i_like_bb_stock who wrote msg# 1463995 Post # of 1464026
trxx rumors of RM into a stem cell co...should fly into pennies imo
Bought TRXX .01
ASYT quickie on tap
Nice call jibber!!
Got in here today at .005, chart looks primmed for northbound move!!
CCTYQ watching, might jump in :))
In SGLS .005
Rheddle, sorry to hear that man, the TA's often do not have current info especially when it's been over a year since they were active, I do believe a year ago BK was being considered but I think the recent news should indicate there is something big in the works!
To be expected with the kinds of pps rise seen this week, thursdays are notorious for cashing out, someone keeps sliding large trades between bid and ask for a reason IMO!!
Appears were gonna get the E tacked on tommorrow, I bet they rush to get that 10k out soon!
Over $570,000 in Dollar Volume
CBAI over $420,000 in Dollar Volume
CBAI over $420,000 in Dollar Volume
Agree, more to come soon, IMO!!
CBAI ran over .02 not long ago, strong earnings out and more to come on earnings for1st quarter 09 soon, easy 5-10 bags
CBAI +25% Big volume Hitting ask on Earnings today
CBAI +25% Big volume Hitting ask on Earnings today
Thanks, looking forward to some fun here!!
ABWTQ Bouncing
Interesting stock, might grab a starter!!
I like the looks of VTSI
ZLUS +85% now
ZLUS +85% now
Big block just hit ask, maybe in preperation for the TV deal
ZLUS +25% on above average volume, 10k coming
Posted by: rheddle Date: Wednesday, April 15, 2009 10:13:57 AM
In reply to: WIDESPREAD PANIC who wrote msg# 907 Post # of 914
** DD POST ** This is a fully reporting company.
Form 4's filed showing CEO buying in February and another one in April:
http://pinksheets.com/edgar/GetFilingHtml?FilingID=6535457
http://pinksheets.com/edgar/GetFilingHtml?FilingID=6373443
CEO buys are mostly above .0015 and his average purchase price has been increasing since the first filing in February, in which he reported one scoop at .0008. Most much higher and as high as .002 so far.
Nice PR this week - the first in months..
Zealous Interactive's Stiletto TV and KJLA TV Sign Broadcast Agreement
http://pinksheets.com/pink/quote/quote.jsp?symbol=zlus#getNews
Chart is close to bottom.
http://stockcharts.com/h-sc/ui?s=zlus
(2.5 million shares propelled this from .001 to .003 on April 13th (the day the PR was released). This shows a pretty low / tightly held float
Low OS:
In the last Q: "As of September 30, 2008 there were 388,245,658 shares of the issuer’s $.001 par value common stock issued and outstanding."
The last Q was filed late and the 10K for 2008 is also being filed late. We should see the 10K any time now.
ZLUS +25% on above average volume, 10k coming
Posted by: rheddle Date: Wednesday, April 15, 2009 10:13:57 AM
In reply to: WIDESPREAD PANIC who wrote msg# 907 Post # of 914
** DD POST ** This is a fully reporting company.
Form 4's filed showing CEO buying in February and another one in April:
http://pinksheets.com/edgar/GetFilingHtml?FilingID=6535457
http://pinksheets.com/edgar/GetFilingHtml?FilingID=6373443
CEO buys are mostly above .0015 and his average purchase price has been increasing since the first filing in February, in which he reported one scoop at .0008. Most much higher and as high as .002 so far.
Nice PR this week - the first in months..
Zealous Interactive's Stiletto TV and KJLA TV Sign Broadcast Agreement
http://pinksheets.com/pink/quote/quote.jsp?symbol=zlus#getNews
Chart is close to bottom.
http://stockcharts.com/h-sc/ui?s=zlus
(2.5 million shares propelled this from .001 to .003 on April 13th (the day the PR was released). This shows a pretty low / tightly held float
Low OS:
In the last Q: "As of September 30, 2008 there were 388,245,658 shares of the issuer’s $.001 par value common stock issued and outstanding."
The last Q was filed late and the 10K for 2008 is also being filed late. We should see the 10K any time now.